These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33350433)

  • 1. Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study.
    Webster-Clark M; Ross RK; Lund JL
    Am J Epidemiol; 2021 Jul; 190(7):1341-1348. PubMed ID: 33350433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
    Filion KB; Yu YH
    Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.
    Suissa S; Moodie EE; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):459-468. PubMed ID: 27610604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study.
    Lin HD; Lai CL; Dong YH; Tu YK; Chan KA; Suissa S
    Drugs Real World Outcomes; 2019 Sep; 6(3):93-104. PubMed ID: 31240630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design.
    Wintzell V; Svanström H; Pasternak B
    Epidemiology; 2022 Sep; 33(5):707-714. PubMed ID: 35944152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative analytic and matching approaches for the prevalent new-user design: A simulation study.
    Webster-Clark M; Mavros P; Garry EM; Stürmer T; Shmuel S; Young J; Girman C
    Pharmacoepidemiol Drug Saf; 2022 Jul; 31(7):796-803. PubMed ID: 35505471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incident user cohorts for assessing medication cost-offsets.
    Stuart B; Loh FE; Roberto P; Miller L
    Health Serv Res; 2014 Aug; 49(4):1364-86. PubMed ID: 24628528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using propensity scores to estimate effects of treatment initiation decisions: State of the science.
    Webster-Clark M; Stürmer T; Wang T; Man K; Marinac-Dabic D; Rothman KJ; Ellis AR; Gokhale M; Lunt M; Girman C; Glynn RJ
    Stat Med; 2021 Mar; 40(7):1718-1735. PubMed ID: 33377193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators.
    Sendor R; Stürmer T
    Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):261-269. PubMed ID: 35019190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis.
    Tran T; Suissa S
    Am J Epidemiol; 2021 May; 190(5):928-938. PubMed ID: 33124647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applied comparison of large-scale propensity score matching and cardinality matching for causal inference in observational research.
    Fortin SP; Johnston SS; Schuemie MJ
    BMC Med Res Methodol; 2021 May; 21(1):109. PubMed ID: 34030640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating medication effects outside of clinical trials: new-user designs.
    Ray WA
    Am J Epidemiol; 2003 Nov; 158(9):915-20. PubMed ID: 14585769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them.
    Fu EL; van Diepen M; Xu Y; Trevisan M; Dekker FW; Zoccali C; Jager K; Carrero JJ
    Clin Kidney J; 2021 May; 14(5):1317-1326. PubMed ID: 33959262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Causal Diagrams to Improve the Design and Interpretation of Medical Research.
    Etminan M; Collins GS; Mansournia MA
    Chest; 2020 Jul; 158(1S):S21-S28. PubMed ID: 32658648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Epidemiologic Toolbox: Identifying, Honing, and Using the Right Tools for the Job.
    Lesko CR; Keil AP; Edwards JK
    Am J Epidemiol; 2020 Jun; 189(6):511-517. PubMed ID: 32207771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.
    Anglemyer A; Horvath HT; Bero L
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):MR000034. PubMed ID: 24782322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More realistic power estimation for new user, active comparator studies: an empirical example.
    Gokhale M; Buse JB; Pate V; Marquis MA; Stürmer T
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):462-6. PubMed ID: 26360635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Sample Size to Attain Statistically Comparable Groups - A Required Data Preprocessing Step to Estimate Causal Effects With Observational Data.
    Kolar A; Steiner PM
    Eval Rev; 2021 Oct; 45(5):195-227. PubMed ID: 34698560
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.